Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;80(5 Suppl 1):15-23.
doi: 10.1590/0004-282X-ANP-2022-S117.

Are we ready to use anti-amyloid therapy in Alzheimer's disease?

Sonia Maria Dozzi Brucki  1 , Karolina Gouveia César-Freitas  1 , Raphael Ribeiro Spera  1 , Conrado Regis Borges  1 , Jerusa Smid  1   2   3
Affiliations
Review

Are we ready to use anti-amyloid therapy in Alzheimer's disease?

Sonia Maria Dozzi Brucki et al. Arq Neuropsiquiatr. 2022 May.

Abstract
in English, Portuguese

Alzheimer's disease (AD) is the most common neurodegenerative disease. Biomarkers have demonstrated that AD pathology exists over the disease continuum from a stage preceding symptoms over 15-25 years to the progressively more impaired symptomatic states, mild cognitive impairment (MCI), and dementia. Biomarkers include: amyloid (Aß), phosphorylated tau, and neurodegeneration. The plasma assays for Aß and tau show great promise for clinical and research use. This review has aimed not only to present the ATN diagnostic classification and the preclinical AD concepts in addressing some possibilities of cognitive assessment instruments, but also to briefly summarize the main anti-amyloid monoclonal antibodies studied in clinical trials. In addition, this paper presents a critical analysis by experts in cognitive neurology while addressing the question as to whether we are prepared for the anti-amyloid therapy era or not.

A doença de Alzheimer (DA) é a doença neurodegenerativa mais comum. Os biomarcadores demonstraram que a patologia da DA existe ao longo do continuum da doença, desde um estágio anterior à sintomatologia, ao longo de 15 a 25 anos, até os estados sintomáticos progressivamente mais prejudicados, comprometimento cognitivo leve (CCL) e demência. Eles subdividem-se em três categorias: amiloide (Aß), tau fosforilada e neurodegeneração. A dosagem de Aß e tau plasmáticos mostra uma grande promessa para uso clínico e de pesquisa. Esta revisão teve como objetivo apresentar a classificação diagnóstica da ATN, os conceitos pré-clínicos da DA e abordar algumas possibilidades de instrumentos de avaliação cognitiva, mas principalmente resumir brevemente os principais anticorpos monoclonais anti-amiloide estudados em ensaios clínicos. Além disso, este artigo apresenta uma análise crítica de especialistas em neurologia cognitiva: estamos ou não preparados para a era da terapia anti-amiloide?

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: There is no conflict of interest to declare.

References

    1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–1590. doi: 10.1016/s0140-6736(20)32205-4. - DOI - PMC - PubMed
    1. Jack CR, Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to revised criteria for the diagnosis of Alzheimer’s disease: National Institute on Aging and the Alzheimer Association Workgroups. Alzheimers Dement. 2011;7(3):257–262. doi: 10.1016/j.jalz.2011.03.004. - DOI - PMC - PubMed
    1. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13. doi: 10.1016/j.jalz.2011.10.007. - DOI - PMC - PubMed
    1. Hardy JA, Higgins GA. Alzheimer’s Disease: The Amyloid Alzheimer’s disease. Science. 1992;256(5054):184–185. - PubMed
    1. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, Veluw SJV. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30–42. doi: 10.1038/s41582-019-0281-2. - DOI - PMC - PubMed